Last reviewed · How we verify
Flomax (tamsulosin)
At a glance
| Generic name | tamsulosin |
|---|---|
| Sponsor | Boehringer Ingelheim |
| Target | 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 7, Alpha-1A adrenergic receptor |
| Therapeutic area | Urology |
| Phase | FDA-approved |
Approved indications
- Benign prostatic hyperplasia
Common side effects
- Dizziness
- Headache
- Asthenia
- Infection
- Back Pain
- Rhinitis
- Chest Pain
- Pharyngitis
Serious adverse events
- Syncope
- Symptomatic Postural Hypotension
- Vertigo
Key clinical trials
- The Efficacy of Nano-water in Combination With Tamsulosin-Dutasteride for Alleviating Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia (NA)
- Medication Facilitated Ureteral Access Sheath Deployment During Ureteroscopy and Endoscopic-Guided Percutaneous Nephrolithotomy: A Randomized Double-Blind Placebo Controlled Trial of Tadalafil, Tamsul (Phase 4)
- Preoperative Administration of Tamsulosin for Prevention of Post Operative Urinary Retention in Males Undergoing Elective Inguinal Hernia Repair (Phase 4)
- Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter: a Randomized Clinical Trial (Phase 3)
- NCT03246880 (Phase 3)
- Comparison of the Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With OAB: A Prospective Randomized Multicenter Study (Phase 4)
- The Efficacy and Safety of Medical Expulsive Therapy After Extracorporeal Shock Wave Lithotripsy (ESWL) in Pediatric Urolithiasis (NA)
- A Phase III, Randomized Clinical Trial to Study the Safety and Efficacy of MK-906 (Finasteride) and Tamsulosin Administered Either Alone or Concomitantly in Patients With Benign Prostatic Hyperplasia (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |